Ihe ngosi nke anọ nke Ameile kwadoro maka ahịa, na-elekwasị anya na ọgwụgwọ adjuvant mgbe ịwa ahụ gasịrị maka ọrịa kansa akpa ume nke na-abụghị obere mkpụrụ ndụ na-akpata mgbanwe EGFR.

Na Mee 9, 2025, Hansoh Pharmaceutical kwupụtara na a kwadoro ihe ngosi ọhụrụ maka Ameile (mkpụrụ ọgwụ almonertinib mesylate) maka ire ahịa. Ihe ngosi ọhụrụ a bụ maka ọgwụgwọ ndị okenye nwere ọrịa kansa akpa ume na-abụghị obere sel (NSCLC) nke etuto ahụ nwere mgbanwe epidermal growth factor receptor (EGFR) exon 19 ma ọ bụ mgbanwe exon 21 (L858R), nakwa ndị a chụpụrụ etuto ahụ. Ameile nwere ihe ngosi anọ akwadoro na China ugbu a, na-anọgide na-abụ isi n'etiti ọgbọ EGFR-TKI nke atọ mepụtara n'ime obodo.

Nkwenye a dabere na nnyocha ARTS (HS-10296-302), nnwale ahụike nke usoro nke atọ nke nwere ọtụtụ etiti, nke a na-achịkwa nke ọma, nke e ji usoro nhazi mee. E gosipụtara nsonaazụ ọmụmụ ihe a dị ka akụkọ ọnụ na Nzukọ Kwa Afọ nke American Association for Cancer Research (AACR) nke 2025.

Data sitere na nnyocha ARTS nke e gosipụtara na Nzukọ Kwa Afọ nke AACR nke 2025 kwadoro na maka ndị ọrịa nwere ọkwa II–IIIB EGFR-mutant NSCLC nke a chụpụrụ kpamkpam, ọgwụgwọ mgbakwunye na Ameile—mgbe ọ dị mkpa—nwere ike ime ka ndụ na-enweghị ọrịa ka mma nke ukwuu. Ọnụego DFS nke afọ 2 ruru 90.2%, yana HR nke 0.17, a na-ejikwa profaịlụ nchekwa zuru oke. N'ụzọ dị mkpa, ọmụmụ ihe ahụ debanyere aha naanị ndị ọrịa China, na-egosipụta arụmọrụ dị mkpa na profaịlụ nchekwa a na-achịkwa nke EGFR-TKI mepụtara n'ime obodo na ndị China.

Banyere Ameile

Dịka ọgwụ EGFR-TKI nke mbụ nke China, Ameile (Aumolertinib Mesilate Tablets) nwere ezigbo liposolubility na nkwụsi ike, na-enye ya ohere ịbanye n'ime ihe mgbochi ọbara-ụbụrụ nke ọma na obere mmeghachi omume ọjọọ. Ugbu a, a kwadoro Ameile maka ihe mgbaàmà anọ: ọgwụgwọ nke abụọ nke ndị ọrịa nwere NSCLC dị elu ma ọ bụ metastatic nwere mgbanwe T790M, bụ ndị gara n'ihu na ma ọ bụ mgbe ọgwụgwọ EGFR-TKI gasịrị; ọgwụgwọ nke mbụ maka ndị ọrịa toro eto nwere NSCLC dị elu ma ọ bụ metastatic nke etuto ahụ nwere nhichapụ EGFR exon 19 ma ọ bụ mgbanwe mgbanwe exon 21 (L858R) dị mma; ọgwụgwọ nke ndị ọrịa nwere kansa akpa ume nke na-abụghị obere sel ("NSCLC") nke ọrịa ha na-aga n'ihu na-esochi ọgwụgwọ chemoradiotherapy dabere na platinum nke etuto ahụ nwere epidermal growth factor receptor ("EGFR") exon 19 deletions ma ọ bụ exon 21 (L858R) dochie mgbanwe mgbanwe; ọgwụgwọ enyemaka nke ndị okenye nwere kansa akpa ume na-abụghị obere sel (NSCLC) nke etuto ahụ ha nwere mgbanwe epidermal growth factor receptor (EGFR) exon 19 ma ọ bụ mgbanwe exon 21 (L858R), ma bụrụkwa ndị e wepụrụ etuto ahụ.

Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.

Nọmba ekwentị: 4008803716

Email：myimmnet@163.com